With the most stocked clinical pipeline among its RNAi peers, Alnylam Pharmaceuticals Inc. has made the leap from platform to products, building on an IP position that has enabled revenue-generating deals that footed the bill for optimizing drug delivery and advancing its internal pipeline.

Now, with three programs in the clinic and a fourth expected to start Phase I this year, Alnylam is on track to meet its goal of five programs in Phase III by 2015.